大胆幅度与临床前阿尔茨海默氏症相关
medRxiv : the preprint server for health sciences
|November 22, 2024
概括
阿尔茨海默病 (AD) 生物标志物显示,即使在认知能力下降之前,大脑活动幅度 (ALFF) 也降低了. 这种大脑功能测量可以检测早期的粉样蛋白和病理,为临床前阿尔茨海默症研究提供了一个敏感的工具.
科学领域:
- 神经成像是一种神经成像.
- 阿尔茨海默氏症疾病研究研究
- 脑功能分析 脑功能分析
背景情况:
- 阿尔茨海默病 (AD) 具有长期的临床前阶段,其中粉样蛋白和病理水平上升,但没有认知能力下降.
- 大脑功能测量可以比结构成像更好地检测早期的AD病理.
- 现有的静态fMRI研究往往忽略了BOLD信号幅度,专注于连接性.
研究的目的:
- 调查临床前和前期AD对BOLD信号中低频波动 (ALFF) 幅度的影响.
- 评估ALFF在整个大脑和中间叶子区域的变化.
- 为了确定ALFF是否对早期的粉样蛋白和蛋白病理敏感.
主要方法:
- 使用静止状态fMRI与血液氧化水平依赖 (BOLD) 对比.
- 在BOLD信号中分析了低频波动 (ALFF) 的幅度.
- 研究了ALFF,粉样蛋白和蛋白病理以及结构变化之间的关联.
主要成果:
- 在临床前和临床前AD中观察到ALFF的减少.
- 粉样蛋白阳性与临床前阿尔茨海默病的广泛ALFF降低相关.
- 在临床前的AD中,tau病理与内腔皮层中ALFF的减少有关.
- 在临床前AD中检测到ALFF变化而没有宏观结构变化.
结论:
- ALFF是一种敏感的生物标志物,用于检测早期AD相关的大脑变化.
- 在结构成像之外,ALFF为早期AD检测提供了额外的灵敏度.
- 在临床前的AD中,ALFF显示为监测针对粉样蛋白的治疗方法的成像生物标志物.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.2K
07:03Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice
Published on: July 31, 2019
6.7K
相关概念视频
Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
